November 20, 2023, Novavax, Inc. (NASDAQ: NVAX) trading session started at the price of $5.75, that was -0.52% drop from the session before. During the day, the shares moved up to $5.75 and dropped to $5.5628 before settling in for the closing price of $5.73. A 52-week range for NVAX has been $5.61 – $21.34.
During the last 5-year period, the sales growth of Healthcare Sector giant was 525.36%. When this article was written, the company’s average yearly earnings per share was at 56.61%. With a float of $110.21 million, this company’s outstanding shares have now reached $118.79 million.
Let’s determine the extent of company efficiency that accounts for 1992 employees. In terms of profitability, gross margin is +54.46, operating margin of -32.53, and the pretax margin is -32.98.
Novavax, Inc. (NVAX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Novavax, Inc. stocks. The insider ownership of Novavax, Inc. is 7.23%, while institutional ownership is 52.96%. The most recent insider transaction that took place on Mar 10, was worth 6,500. In this transaction President, R&D of this company bought 1,000 shares at a rate of $6.50, taking the stock ownership to the 14,473 shares. Before that another transaction happened on Mar 07, when Company’s President, R&D bought 2,000 for $7.04, making the entire transaction worth $14,088. This insider now owns 13,473 shares in total.
Novavax, Inc. (NVAX) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/29/2023, it has been observed that the corporation posted -$1.26 earnings per share (EPS) during the time that was better than consensus figure (set at -$1.83) by $0.57. This company achieved a net margin of -33.20. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 56.61% per share during the next fiscal year.
Novavax, Inc. (NASDAQ: NVAX) Trading Performance Indicators
You can see what Novavax, Inc. (NVAX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.38, a number that is poised to hit 0.16 in the next quarter and is forecasted to reach -0.80 in one year’s time.
Technical Analysis of Novavax, Inc. (NVAX)
Looking closely at Novavax, Inc. (NASDAQ: NVAX), its last 5-days average volume was 6.14 million, which is a drop from its year-to-date volume of 7.3 million. As of the previous 9 days, the stock’s Stochastic %D was 5.17%. Additionally, its Average True Range was 0.43.
During the past 100 days, Novavax, Inc.’s (NVAX) raw stochastic average was set at 2.90%, which indicates a significant decrease from 7.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.84% in the past 14 days, which was lower than the 84.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.88, while its 200-day Moving Average is $7.69. However, in the short run, Novavax, Inc.’s stock first resistance to watch stands at $5.78. Second resistance stands at $5.86. The third major resistance level sits at $5.97. If the price goes on to break the first support level at $5.59, it is likely to go to the next support level at $5.48. Now, if the price goes above the second support level, the third support stands at $5.40.
Novavax, Inc. (NASDAQ: NVAX) Key Stats
There are 118,790K outstanding shares of the company, which has a market capitalization of 677.10 million. As of now, sales total 1,982 M while income totals -657,940 K. Its latest quarter income was 186,990 K while its last quarter net income were -130,780 K.